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The Urgent Need 
for Expanded 
Response Options
Canada is facing an urgent challenge 
to reduce the harms associated 
with the problematic use of opioids. 
More than 14,700 lives were lost 
to deaths apparently related to 
opioids between January 2016 
and September 2019. During that 
same period, there were 19,490 
hospitalizations for poisoning 
related opioid to opioids (Special 
Advisory Committee on the Epidemic 
of Opioid Overdoses, 2019). The 
COVID-19 pandemic compounds this 
ongoing public health crisis. There 
is a heightened need to reduce 
avoidable pressures on healthcare 
systems and support people who 
use opioids who may be at increased 
risk or unable to self-isolate during 
the pandemic.
Individuals using opioids need a 
range of comprehensive, accessible, 
quality services to support them if 
they choose to reduce or stop, but 
available treatment options are 
limited. Many individuals with lived 
or living experience, as well as public 
health and medical professionals, 
are calling for pharmaceutical-grade 
opioids to be made available to treat 
persons with opioid use disorder 
(OUD), and to stem the deaths 
occurring from the contaminated 
illicit opioid supply (Canadian 
Community Epidemiology Network on 
Drug Use, 2020).
There is evidence that injectable 
hydromorphone or diacetylmorphine 
therapies are viable treatment 
options for patients with severe OUD 
(Fairbarin et al., 2019). Further, 
administering these therapies in 
primary care clinics and designated 
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KEY MESSAGES
•	The COVID-19 pandemic continues to compound the ongoing 
public health crisis related to high rates of opioid overdoses 
and deaths.
•	Access to a greater range of pharmaceutical treatment options 
for opioid use can substantially improve the likelihood that 
clients remain in treatment, improve the quality of life for people 
who use opioids and help reduce deaths from a contaminated 
illicit opioid supply.
•	Fully responding to opioid harms requires addressing 
fundamental problems of regulated and safer supply and mental 
health, trauma and the social determinants of health.
•	Recent legislative changes in Canada have increased the 
availability of diacetylmorphine and hydromorphone, two 
pharmaceutical treatment options for opioid use disorder. 
Additional class exemptions issued by Health Canada in the 
context of COVID-19 have further reduced barriers to accessing 
pharmaceutical options.
•	Response needs to involve collaborative decision making involving 
people with lived or living experience of opioid use, who are well 
positioned to anticipate unintended consequences and identify 
effective solutions.
•	There is a need to support physician and pharmacist competency 
and engagement, as they play a pivotal role in moving toward 
broader implementation of expanded options.
2 Exploring Expanded Response Options to Opioid Harms    Canadian Centre on Substance Use and Addiction
pharmacies is feasible and cost 
efficient. This integration can 
provide the opportunity to address 
additional primary care needs 
in parallel, potentially leading 
to positive short-term outcomes 
such as stopping illicit opioid use, 
reducing criminal activity and 
transitioning into stable housing 
and employment (Wilson, Brar, 
Sutherland, & Nolan, 2020).
Comprehensive efforts have 
been made across the country 
to address the multiple factors 
contributing to the opioid crisis and 
minimize ongoing harms, with some 
strategies more widely implemented 
than others. For example, naloxone, 
an emergency measure that can 
reverse an overdose, has become 
widely available across Canada 
(Moustaqim-Barrette et al., 2019). 
In contrast, the availability of opioid 
agonist therapies (OAT) can vary by 
jurisdiction and region, as well as 
with physician competence (Herring, 
Lefebvre, Stewart, & Selby, 2014; 
Taha, 2018). 
While these case studies highlight 
injectable OAT options, providing an 
array of flexible options for delivery 
and administration of treatment 
during the pandemic can support 
people who use opioids by reducing 
the risk of overdose, infection and 
withdrawal while they maintain 
physical distancing or must 
self-isolate. Health Canada has 
recently issued a class exemption 
under subsection 56(1) of the 
Controlled Drugs and Substances 
Act that increases the accessibility 
of controlled substances for 
therapeutic purposes (Health 
Canada, 2020), and British 
Columbia has issued interim 
clinical guidance for putting these 
exemptions into place (British 
Columbia Centre on Substance 
Use, 2020).
This resource provides case 
studies of the expanded response 
options to opioid harms used by 
four Canadian clinics in 2019. 
These case studies are intended 
to share information and generate 
discussion about alternative 
complementary measures for 
improving the quality of life of 
people who use opioids, especially 
those with severe OUD, and the 
value of implementing expanded 
responses to reducing opioid 
harms. The resource is intended 
“I don’t think harm reduction is different than 
recovery. It’s all about someone just living 
their best life and being happy and meeting 
their goals and whether or not they use 
drugs I think is irrelevant. … we want people 
to be alive, not get HIV, and live with joy in 
their life with other human connections, and 
that’s what these programs do. And whether 
or not you call that recovery is up to you.”
— Christy Sutherland, MD, Portland Hotel 
Society, Vancouver and Victoria
“We try to optimize their treatment as best 
we can, but some participants really feel like 
substance use is a part of who they are and 
at this moment they are not going to stop the 
use, and that’s okay, too. So, they can still 
come here, it’s not that they are going to be 
stigmatized or removed from the program 
because of their ongoing substance use and 
it’s sort of like trying to have harm reduction 
and treatment coincide with each other, that 
they are not these opposing ideas, that they 
can actually exist together.”
— Tara O’Mara, NP, Alberta Health Services, 
Edmonton
ACKNOWLEDGEMENTS
We are grateful to the following participants who offered their time and shared their experience for the 
case studies:
•	Scott MacDonald, MD, Providence Healthcare, Vancouver
•	Tara O’Mara, NP, Alberta Health Services, Edmonton
•	Christy Sutherland, MD, Portland Hotel Society, Vancouver and Victoria 
•	Jeffrey Turnbull, MD, Ottawa Inner City Health, Ottawa
Canadian Centre on Substance Use and Addiction    Exploring Expanded Response Options to Opioid Harms 3
for a broad audience including 
mental health and addiction 
service providers, harm reduction 
service providers, primary care and 
clinic physicians and nurses, first 
responders, pharmacists, policy 
makers, researchers and people 
who use drugs. The case studies 
were conducted before the onset 
of the COVID-19 pandemic. Since 
then, in response to the need for 
social isolation, a greater flexibility 
in response options is being 
explored in Canada and many other 
countries around the world.
Key Learnings for 
Injectable Opioid 
Therapy
The four clinics that provided 
information for this report are 
profiled below. The small sample 
means it is not possible to draw 
general conclusions. Furthermore, 
the distribution of participants 
across Canada was not equal 
and the findings may not be 
representative of experiences 
in all regions. Nevertheless, the 
case studies shine a spotlight on 
Canadian examples of current 
practice for expanded options to 
address OUD. The findings from 
practice were supplemented with 
those from the literature:
•	The case study participants 
identified low-barrier access to 
treatment, open-ended time 
for physician engagement and 
ongoing evaluation of treatment 
CLINIC PROFILES
Four clinics were contacted for this study. Three are outpatient clinics and one is a residential program. 
Clinics are located in Alberta, British Columbia and Ontario. Their treatment services integrate harm reduction 
approaches and place them on a single continuum of care. Some patients use the clinics or program as an 
avenue for “safer supply.” 
Each clinic or program supports 20–150 individuals, 
depending on capacity. Patients of the clinics or 
program must meet the following criteria:  
•	Use drugs intravenously 
•	Be diagnosed with OUD
•	Be at risk of overdose
•	Have a history of unsuccessful oral treatment
Patients enter the clinics and programs via:
•	Self-referral
•	Referral from other clinics and programs
•	Connection through supervised consumption sites
The clinics and programs offer a variety of medical 
response options to opioid harms that include:
•	Preloaded syringes of hydromorphone provided 
for client to inject while supervised or for nurse to 
assist (80–630 mgs over 3–6 doses per day)
•	Hydromorphone tablets crushed by nurses and 
sterile injectable equipment provided to patients to 
administer (16 mgs, up to five times per day)
•	Preloaded syringes of diacetylmorphine provided 
to client for supervised injection or for a nurse to 
assist (up to 400 mg in three doses per day to a 
maximum daily dose of 1,000 mg)
The clinics offer the following additional services:
•	Primary care
•	HIV and hepatitis C treatment
•	Women’s health
•	Chronic disease management (e.g., chronic 









Clinics report the following outcomes:
•	 Improved health, hygiene and nutrition
•	Reconnection with family
•	Employment
•	Engagement in leisure activities
•	Decreased criminality
•	Fewer or no overdoses
•	Connections with other services
	◦ Psychiatry
	◦ Initiation of HIV or hepatitis C treatment
	◦ Housing support
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programs as key factors 
for success. 
•	An additional success factor 
of including people with lived 
or living experience in decision 
making to determine appropriate 
responses, identify effective 
solutions and anticipate 
unintended consequences is 
supported by the literature (Taha, 
Maloney-Hall, & Buxton, 2019).
•	The case studies demonstrate 
that quality of life for people who 
use opioids can be substantially 
improved across multiple 
dimensions by providing access to 
a greater range of pharmaceutical 
treatment options. 
•	 It remains essential to address 
underlying problems related to 
mental health conditions, trauma 
and the social determinants of 
health in support of the response 
to opioid harms (Canadian 
Centre on Substance Use and 
Addiction, 2017).
•	Policy levers, such as 
those addressing physician 
remuneration and billable time 
for engagement, can help move 
the identified factors for success 
forward (Childerhose, Atif, & 
Fairbank, 2019).
•	Participants noted that addressing 
privacy restrictions that inhibit 
information sharing among clinics 
and programs could be a further 
contributor to success.
•	 Injectable opioid agonist therapy 
can be safely transitioned to a 
designated community pharmacy 
upon dose stabilization (Wilson 
et al., 2020).
•	Challenges to program delivery 
identified by the case study 
participants include reliable 
funding for medications and 
staffing, harms to clients who 
use substances other than 
opioids and opposition to using 
expanded response options from 
colleagues, other healthcare 
services or correctional facilities.
•	The case study respondents 
reported that men tended to 
access the clinics and programs 
more than women. Some women, 
particularly those involved in the 
sex trade, or those who prefer 
assisted injection or want to inject 
in an area that they do not want to 
expose (such as their chest), are 
uncomfortable or feel threatened 





The social distancing required as 
part of the response to the COVID-19 
pandemic has forced policy 
makers to create new guidelines 
to ensure programs continue to 
support people with lived and living 
experience while respecting these 
requirements. These new practices 
will need to be revisited and 
evaluated to identify practices to 
continue post-pandemic.
The case study participants 
proposed the following 
considerations for implementing 
expanded response options, 
depending on the needs of the 
community: 
•	Family doctors could work with 
their community pharmacy to 
ensure expanded response 
options are available at 
their clinics. 
•	After developing a relationship 
with a person who uses opioids, 
“We already have evidence that injectable 
hydromorphone is safe, and both more 
effective and more cost-effective in that 
population that continues to inject despite 
attempting oral treatments. But now we also 
know that it reduces mortality. It needs to be 
available and it will be available.”
— Scott MacDonald, MD, Providence 
Healthcare, Vancouver
“We need to know what the values, goals 
and individual plans are for each patient. It 
does need to be individualized, and there 
needs to be opportunity for shared care. 
That may include, well, which drug do you 
want? Would you prefer diamorphine or 
hydromorphone? We should be respecting 
people’s decisions. When somebody is 
ready to transition to oral, then, how would 
you like to do that? Do you want to do micro 
dosing with Suboxone? Do you want to try 
methadone? A taper or Kadian? We give 
people choice.”
— Scott MacDonald, MD, Providence 
Healthcare, Vancouver
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care providers may wish to 
consider if there are opportunities 
to connect them to additional 
external services.
•	Specialized services may be 
needed in some communities 
to address particular 
population concerns. 
Participants noted additional solutions 
to help improve quality of care: 
•	Provide women-only programs;
•	Produce diacetylmorphine 
domestically to improve access;
•	 Increase the capacity of programs 
to accommodate more patients; 
and
•	Develop take-home programs to 
minimize the toll on patients’ and 
services providers’ time.
Supports for Physician 
Competence
The case study participants noted 
that physicians might not feel fully 
confident in this aspect of their 
practice because of the need 
for holistic skills encompassing 
addiction, mental health and public 
health expertise. They explained 
that physician competence typically 
develops over time, but also 
suggested the following supports 
for physicians to improve their 
competence: 
•	Regularly review the literature; 
•	Respond to calls for change in 
practice;
•	Attend physician training courses;
•	Use point-of-care modules; and
•	Find opportunities for mentorship 
and access to specialist supports. 
Evaluation and Knowledge 
Mobilization
Evaluation of the impact of these 
programs, including a focus on 
unique implementation needs for 
particular populations and programs, 
will contribute to the evidence base. 
Continued knowledge mobilization 
of the outcomes achieved by people 
accessing these clinics and programs 
is necessary to propel discussion 
about the value of implementing 
expanded responses to opioid harms.
Conclusion and 
Next Steps
These case studies profile the 
expanded response options to opioid 
harms used by four Canadian clinics. 
The intent is to fuel discussion 
about alternatives for improving the 
quality of life for people who use 
opioids and the value of expanded 
responses to reducing opioid harms. 
This discussion is particularly 
important during the COVID-19 
pandemic, which is compounding the 
ongoing public health crisis of opioid 
overdoses and deaths. The lessons 
learned from these case studies 
can inform efforts to implement 
expanded response options for opioid 
harms. These efforts could include:
•	Expanding the scope of treatment 
options available due to the 
urgent need to respond to 
the COVID-19 pandemic and 
evaluating the impact of these 
changes in practice to determine 
what could be sustained after the 
pandemic;
•	Supporting the implementation 
of identified good practices and 
trialing solutions to recognized 
problems, including finding ways 
to address fundamental problems 
related to underlying mental 
health conditions, trauma and the 
social determinants of health;
•	Supporting physicians to develop 
competence in delivering these 
treatments through literature 
reviews, training, point of care 
models, and mentorship and 
specialist supports;
•	Rigorously investigating the 
effectiveness of these types of 
programs and the improvements 
they claim through randomized 
control trials and program 
evaluation; and
•	Broadly sharing new knowledge 
with policy makers, researchers, 
the full range of potential service 
providers, and persons who use 
substances and their supporters 
and allies.
“In a supervised injection site, the immediate 
goal is safety, getting the chaos out of their 
life, connecting with other things that are 
important for their addiction management, 
such as a psychiatrist, counselling, family, 
employment, leisure.… we watch them 
inject, and they overdose, and we give them 
Narcan, and we send them on their way, 
only to do it again. If we [can] stabilize them, 
keep them alive, and then work on their 
addiction, that seem[s] to be a much more 
effective strategy. And yeah, if we could get 
them to oral, that would be fantastic. If we 
could get them abstinent, working, all of 
those things, that would be fantastic too. But 
really, it’s not my objectives. It’s theirs.”
— Jeffery Turnbull, MD, Ottawa Inner City 
Health, Ottawa
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Additional Resources 
• Canadian Centre on Substance Use and Addiction, Impacts of COVID-19 on 
Substance Use
• Canadian Centre on Substance Use and Addiction, Opioids
• Health Canada, Subsection 56(1) class exemption for patients, practitioners and 
pharmacists prescribing and providing controlled substances in Canada during the 
coronavirus pandemic 
• Health Canada, Opioid Symposium: What We Heard Report 
• Health Canada, Toolkit for Substance Use and Addictions Program Applicants. Stream 
2 — Increase access to pharmaceutical grade medications. Available upon request from 
hc.SUAP-PUDS.sc@canada.ca with “Safe Supply Tools” in the subject line.
• Canadian Research Initiative in Substance Misuse (CRISM), National Guideline for the 
Clinical Management of Opioid Use Disorder
• CRISM, COVID-19 Pandemic — National Rapid Guidance. CRISM provides six national 
guidance documents that address the urgent needs of people who use substances, 
service providers and decision makers in relation to the COVID-19 pandemic. (Some 
documents forthcoming and yet to be provided in French.)
• Centre for Health Evaluation and Outcome Sciences, Evidence Summary: 
Dextroamphetamine Sulfate (Dexedrine spansule) for the Treatment of Stimulant 
Use Disorder 
• Public Health Ontario, Effectiveness of Supervised Injectable Opioid Agonist Treatment 
(SiOAT) for Opioid Use Disorder
• Safer Opioids Supply Programs, A Harm Reduction Informed Guiding Document for 
Primary Care Teams 
• British Columbia Centre on Substance Use, Guidance for Injectable Opioid Agonist 
Treatment for Opioid Use Disorder
• CRISM, Injectable Opioid Agonist Treatment Guideline
• Health Canada, Toolkit: COVID-19 and Substance Use. Available upon request from 
hc.cdss-scdas.sc@canada.ca
• Canadian Association of People Who Use Drugs, Safe Supply Concept Document
• Canadian Family Physician Clinical Practice Guidelines, Managing Opioid Use Disorder in 
Primary Care: PEER Simplified Guideline
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